Recent 8-K filings for ULBI

• May 8, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Ultralife Q1 revenue $47.4M, GAAP EPS -$0.03; backlog record $115.1M

  Revenue $47.4M, down 6.5% YoY; Battery & Energy sales -4.7%, Communications Systems -25.7%.

• March 10, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Ultralife Q4 revenue $48.5M, but operating loss of $10.6M on $12.2M impairment; GAAP EPS ($0.45)

  Revenue $48.5M (+10.6% YoY); operating loss ($10.6M) vs profit $1.5M last year, driven by $12.2M intangible asset impairment.

• November 18, 2025, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Ultralife Q3 sales up 21.5% to $43.4M; GAAP loss per share of $0.07 on Calgary closure charge

  Sales $43.4M (+21.5% YoY, including Electrochem); organic growth 2.5%. Backlog $90.1M vs $84.5M at Q2 2025.

• August 7, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Ultralife Q2 revenue up 13% to $48.6M on Electrochem; margin down, GAAP EPS $0.05 vs $0.18

  Sales $48.6M (+13% YoY); organic Battery & Energy flat, Communications Systems down 57.2% to $2.7M.

• May 9, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Ultralife Q1 revenue $50.7M (+21% YoY); GAAP EPS $0.11 vs $0.18

  Revenue $50.7M, up 21% YoY; Battery & Energy Products +32.4% to $46.3M (incl. Electrochem, organic +10.6%).

• April 1, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Ultralife Q4 GAAP EPS $0.01 vs $0.17 YoY; sales $43.9M; backlog $102.2M

  Q4 sales $43.9M, down from $44.5M YoY; Battery & Energy +11.7%, Communications -55.1%.

• January 16, 2025, 6:59 PM ET M&A materiality 0.80 neutral item 9.01

  Ultralife files amended 8-K with audited financials for Electrochem acquisition

  Ultralife Corporation (ULBI) filed an 8-K/A on Jan 16, 2025, amending its Nov 6, 2024 report.

• November 8, 2024, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Ultralife Q3 EPS $0.02 vs $0.08; revenue $35.7M (-9.6%); backlog $78M

  GAAP diluted EPS $0.02, down from $0.08; net income $0.3M vs $1.3M Q3 2023.

• November 6, 2024, 6:59 PM ET M&A materiality 0.80 positive item 1.01item 2.01item 2.03item 7.01item 9.01

  Ultralife completes $50M acquisition of Electrochem Solutions; secures $55M term loan

  Acquired all shares of Electrochem from Integer Holdings (NYSE: ITGR) for $50M cash on Oct 31, 2024.

• October 3, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 7.01item 9.01

  Ultralife acquires Electrochem Solutions for $50M; expects EPS accretive in 2025

  Purchase price $50M cash; transaction expected to close by end of October 2024.

• July 25, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Ultralife Q2 sales $43.0M (+0.7%); Battery segment record; debt cut 52% to $12.1M

  Sales $43.0M vs $42.7M; Battery & Energy Products segment record $36.7M, up 8.3% YoY.

• April 25, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Ultralife Q1 sales up 31.4% to $41.9M; GAAP EPS $0.18 vs -$0.02 YoY

  Revenue $41.9M (+31.4% YoY); government/defense sales +83.4%, medical battery sales +54.7%.

• February 15, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Ultralife Q4 revenue $44.5M (+23.4% YoY); adjusted EPS $0.18 vs -$0.03

  Q4 2023 sales $44.5M, up 23.4% YoY; full-year sales $158.6M, up 20.3%.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

5 positive 6 negative 5 neutral

source · ULBI on sec.gov